Drug intelligence / Profile preview

imn-006

Development stage: Unknown
Lead developer: Immuneel Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

IMN-006 is an investigational autologous CAR-T cell therapy targeting B-cell maturation antigen (BCMA), developed by Immuneel Therapeutics. It is designed as a BCMA inhibitor for the treatment of hematologic malignancies, particularly multiple myeloma. The drug works by engineering a patient's own T cells to express a chimeric antigen receptor that recognizes and binds to BCMA, leading to targeted destruction of malignant plasma cells expressing this antigen. As of December 2024, IMN-006 is in Phase 1/2 clinical development for multiple myeloma and other hematologic neoplasms[1][4][5].

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on imn-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on imn-006.

Explore the full profile